Postherpetic Neuralgia News and Research

RSS
FDA grants approval for generic versions of Lyrica

FDA grants approval for generic versions of Lyrica

Adults skipping vaccines may miss out on effective new shingles shot

Adults skipping vaccines may miss out on effective new shingles shot

CDC recommends new vaccine for shingles

CDC recommends new vaccine for shingles

New shingles vaccine gets FDA panel votes

New shingles vaccine gets FDA panel votes

Study: Chickenpox vaccination increases incidence of shingles in younger adults

Study: Chickenpox vaccination increases incidence of shingles in younger adults

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Researchers determine safety and effectiveness of neurostimulation to treat chronic pain

Researchers determine safety and effectiveness of neurostimulation to treat chronic pain

SCILEX completes patient enrollment to study Ztlido for treatment of postherpetic neuralgia

SCILEX completes patient enrollment to study Ztlido for treatment of postherpetic neuralgia

Treating long wait-times dictate long-term success of spinal cord stimulation therapy

Treating long wait-times dictate long-term success of spinal cord stimulation therapy

Loyola physician sheds light on common and painful viral infection, shingles

Loyola physician sheds light on common and painful viral infection, shingles

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Treatments for peripheral neuropathic pain compared

Treatments for peripheral neuropathic pain compared

Once-daily Gralise significantly reduces pain intensity in PHN patients

Once-daily Gralise significantly reduces pain intensity in PHN patients

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN